Myeloid Sarcoma: An Overview.

Myeloid Sarcoma (MS) is a rare, high-grade, hematological malignancy defined as an extramedullary tumor mass of neoplastic myeloid blasts with or without maturation that effaces tissue architecture.1,2 MS is considered equivalent to acute myeloid leukemia (AML). Diagnosis requires tumor biopsy, which should be accompanied by bone marrow evaluation for medullary disease. It is recommended that MS be treated like AML. Additionally, ablative radiotherapy and novel targeted therapies may also be beneficial.

Our knowledge of MS remains poor due to its rarity, remarkably immunophenotypic, genetic, and clinical heterogeneity, and apparently inconsistent findings from MS studies. While genetic profiling has identified recurrent genetic abnormalities including gene mutations associated with MS, the mechanism by which MS homes to specific organs remains unclear; the latter may arise due to aberrancy of chemokines, cytokines, and cellular adhesion molecules. This article aims to review the current literature as it pertains to MS pathogenesis, diagnosis, and genetic findings associated with their limitations in study design and to present the frameworks for the future studies.

留言 (0)

沒有登入
gif